Procyrion, Inc. to Present Circulatory Support Pump at International Society for Heart and Lung Transplantation’s Annual Meeting


HOUSTON, TX (April 1, 2014) - Procyrion’s team of life science entrepreneurs have been accepted to present Aortix™, an intra-aortic ambulatory support device for cardiorenal heart failure patients, at the International Society for Heart and Lung Transplantation’s (ISHLT) 34th Annual Meeting & Scientific Session in San Diego April 10 – 13, 2014.

Procyrion’s research abstract was reviewed and accepted by the ISHLT Abstract Selection Committee comprised of scientists, infectious disease specialists, tissue engineers and leading surgeons from around the world.Consisting of a small, continuous flow pump mounted within a self-expanding anchoring system, the small size and unique design of Aortix™ enable a minimally invasive outpatient procedure that takes about ten minutes to complete.  The device is expected to provide a treatment option for the more than two million chronic heart failure patients who are too sick for medication.

ISHLT’s annual meeting and scientific session focuses on the advancement of the science and treatment of end-state heart and lung disease.  The four-day conference will offer new insights into some of the most intriguing and provocative areas of Heart Failure and Transplant Medicine and Heart Transplantation; showcase clinical care and research initiatives through a diverse program of informative sessions relevant to the nursing, health science and allied health community; and highlight the latest in Mechanical Circulatory Support scientific investigation.

Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use.  The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.  For more information, visit or call 713.579.9227.

Read More